BioSpace News Archive

RedHawk Holdings Corp., a diversified holding company primarily engaged in sales and distribution of medical devices, announced that it has received an order to supply the City of New York with an expedited delivery for 2,000 of its digital non-contact thermometers.

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019.

MBio Diagnostics announced an expanded scope contract with the US Defense Advanced Research Projects Agency, where DARPA will apply additional resources and funds to accelerate progress towards FDA approval for MBio’s LightDeck® platform.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) today announced that it has completed its previously announced redemption all of its outstanding 15% unsecured debentures issued November 8, 2019 (the “Debentures”) at a price equal to 110% of the principal amount of the Debentures (the “Redemption Price”).

Several media reports of cases of pulmonary fibrosis resulting from COVID-19 disease have raised important questions in the pulmonary fibrosis community.

Prisma Health announced that it is collaborating with Ethicon Inc., part of the Johnson & Johnson Medical Devices Companies, to make and distribute a ventilator expansion device, called the VESper™ Ventilator Expansion Splitter.

Chemical Insights, an Institute of Underwriters Laboratories, announced the findings from its research collaboration with Duke University on the influence of outdoor and indoor air pollution on asthmatic children was published in JAMA Pediatrics, a journal of the American Medical Association.

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announced that it has entered into agreements (“the Agreements”) with Acrotech Biopharma LLC,

Taro Pharmaceutical Industries Ltd. announced the appointment of Daphne Huang as Vice President, CFO and Chief Accounting Officer